Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012; Massachusetts Medical Society; Volume: 367; Issue: 19 Linguagem: Inglês
10.1056/nejmoa1209124
ISSN1533-4406
AutoresSunil Verma, David Miles, Luca Gianni, Ian E. Krop, Manfred Welslau, José Baselga, Mark D. Pegram, Do‐Youn Oh, Véronique Dièras, Ellie Guardino, Fang Ting Liang, Michael W. Lu, Steven R. Olsen, Kim T. Blackwell,
Tópico(s)Click Chemistry and Applications
ResumoTrastuzumab emtansine (T-DM1) is an antibody–drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)–targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1. The antibody and the cytotoxic agent are conjugated by means of a stable linker.
Referência(s)